Acadia Pharma (ACAD) Reports Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
Go back to Acadia Pharma (ACAD) Reports Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 27.29 -0.16 (0.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.45 | 52 Week High | $42.49 | |||
| Open | $27.37 | 52 Week Low | $16.64 | |||
| Day High | $27.48 | P/E | N/A | |||
| Day Low | $26.73 | EPS | $-0.42 | |||
| Volume | 5,482,713 | |||||
